



DELPHI INITIATIVE RECOMMENDATIONS ON EARLY-ONSET COLORECTAL CANCER (DIRECT)

THE PATH TO IMPROVE DIAGNOSIS AND CLINICAL MANAGEMENT

September 1st-2nd 2022

Congress Venue: Palazzo Clerici, Via Clerici 5, Milan, Italy

PRELIMINARY PROGRAMME

PRESIDENT OF THE MEETING

Giulia Martina Cavestro

CO-PRESIDENTS OF THE MEETING

Gabriela Moslein

President “European Hereditary Tumour Group” (EHTG)

Cristina Oliani

President “Associazione Italiana Familiarità Ereditarietà Tumori” (AIFET)

Swati G. Patel

President “The Collaborative Group of the Americas on Inherited Gastrointestinal Cancer” (CGA-IGC)

SCIENTIFIC SECRETARIAT

Marta Puzzono

Alessandro Mannucci

=====
===
INTRO SPEECH

The incidence of colorectal cancer before the age of 50 is increasing. Patients with early-onset colorectal cancer (eoCRC) are managed according to CRC guidelines that are not specific for this age group. A multidisciplinary international group (DIRECT) was convened to develop the first evidence-based consensus recommendations for the management of eoCRC.

The DIRECT group produced 28 statements in 7 areas of interest: diagnosis, screening, genetics, pathology-oncology, endoscopy, therapy, and end-stage disease.

These are the first evidence-based consensus recommendations on eoCRC.

=====
===

PRELIMINARY PROGRAMME

September 1st – Morning

8.30 am-8.50 am **Giulia Martina Cavestro, Swati G. Patel, Cristina Oliani, Gabriela Moslein, Silvio Danese**

8.50 am-9.00 am **Fondazione Menarini**

Welcome greetings

DIAGNOSIS OF EOCRC

MODERATORS: **Matthew B. Yurgelun, Andrea Cercek, Cathy Eng**

09.00 am -9.20 am **Caitlin Murphy**. What is the global epidemiology and age cut-off to define eoCRC? Summary from the “*DIRECT*” recommendations and update from the last-year literature.

9.20 am -9.40 am **Sonia Kupfer**. Which symptoms and clinical signs prompt evaluation for eoCRC? Summary from the “*DIRECT*” recommendations and update from the last-year literature.

9.40 am-10.00 am **Swati Patel**. Which test(s) and what should be the time frame for evaluation of symptoms and signs of eoCRC? Summary from the “*DIRECT*” recommendations and update from the last-year literature.

10.00 am-10.20 am Panel Discussion

10.20 am-10.40: Coffee Break

eoCRC SCREENING

MODERATORS: **Andrew Latchford, Patrik Lynch, Charles Kahi**

10.50 am-11.10 am: Should population screening for CRC begin before the age of 50? Summary from the “*DIRECT*” recommendations and update from the last-year literature.

- 10.50 am-11.05 am: PROS: **Elena Stoffel**
- 11.05 am-11.20 am: CONS: **Evelien Dekker**

11.20 am- 11.40 am **Maria De Los Angeles Daca-Alvarez.** How can family history influence in eoCRC detection? What other risk factors in assessing an individual's risk for eoCRC? Summary from the "DIRECT" recommendations and update from the last-year literature.

11.40 am-12.00 am Panel Discussion

12.00 am-12.20 Lecture **Clement Richard Boland: Role of epigenetics in eoCRC**

Introduction: Luigi Laghi

12.30 am-13.30pm: Lunch

September 1st – Afternoon

GENETICS OF eoCRC

MODERATORS: **Sapna Syngal, Pal Moller, Zsofia K Stadler**

14.00 pm-14.30 pm **Mev Dominguez Valentin.** Who should receive germline genetic testing among eoCRC patients, and when should this take place? Summary from the "DIRECT" recommendations and update from the last-year literature.

How do polygenic risk scores have the potential to impact eoCRC in the future? Summary from the "DIRECT" recommendations and update from the last-year literature.

14.30 pm-14.50 pm **Heather Hampel.** What genes should/could be included in germline multi-gene panel tests for eoCRC patients? Summary from the "DIRECT" recommendations and update from the last-year literature.

14.50 pm-15.10 pm **Fay Kastrinos.** Could risk assessment tools be helpful for eoCRC patients? Summary from the "DIRECT" recommendations and update from the last-year literature.

15.10 pm-15.30 pm Panel Discussion

15.30 pm-16.00 pm: Coffee Break

INTERNATIONAL COLLABORATION PROPOSALS

Moderators: **Eduardo Vilar, Ajay Goel, Alberto Bardelli**

16.00 pm-16.10 pm **Marta Puzzono.** Demetra Project.

16.10 pm-16.20 **Pal Moller.** PLSD update.

16.20 pm-16.30 pm **Satish K Singh.** Artificial Intelligence-Based Assessment of Colorectal Polyp Histology by Elastic-Scattering Spectroscopy before the age of 50.

16.30 pm-16.40 pm **Desmond Winter.** The “REACCT Collaborative”

16.40 pm-16.50 pm **Alessandro Mannucci.** Refining the age of CRC screening.

16.50 pm-17.00 pm *To be decided.*

17.00 pm-17.10 pm *To be decided.*

17.10 pm-17.20 pm *To be decided.*

17.20 pm-17.30 pm *To be decided*

September 2nd – Morning

8.00 am-8.10 am **Giulia Martina Cavestro**, Welcome greetings

eoCRC ONCOLOGICAL PATH

MODERATORS: **Vincenzo Valentini, Renato Cannizzaro, Salvatore Siena**

8.10 am-8.20 am **Stefano Cascinu**. How to decide adjuvant postoperative treatment. Summary from the “*DIRECT*” recommendations and update from the last-year literature.

8.20 am-8.40 am **Elisa Meldolesi**. How to decide neoadjuvant treatment in eoCRC? Who to give it to and what to give? Summary from the “*DIRECT*” recommendations and update from the last-year literature.

8.40 am-9.00 am Panel Discussion

eoCRC PERSONALIZED MEDICINE

MODERATORS: **Emanuele Damiano Urso, Clement Richard Boland, Peter P. Stanich**

9.00 am-9.20 am **Andrea Remo**. Is immunohistochemistry/molecular microsatellite analysis for mismatch repair proteins necessary in eoCRC endoscopic biopsies? Molecular markers for selection of targeted treatments in patients with eoCRC. Summary from the “*DIRECT*” recommendations and update from the last-year literature.

9.20 am-9.40 am **Enrico Papaleo**. Which criteria to select patients for fertility preservation and which information needs to be provided to preserve fertility and fecundity before and after treatment? Summary from the “*DIRECT*” recommendations and update from the last-year literature.

9.40 am-10.00 am Panel Discussion

10.00 am-10.20 pm: Coffee Break

eoCRC ENDOSCOPIC PATH

Moderators: **Carol A. Burke, David Liska, Kevin Monahan**

10.20 am-10.40 am **Elena Stoffel** What endoscopic technologies, standard quality metrics and follow-up schedule for eoCRC being treated either endoscopically or surgically? Summary from the “*DIRECT*” recommendations and update from the last-year literature.

10.40 am-11.00 am **Evelien Dekker**. Is there a place for endoscopic therapy of T1 cancers in patient with eoCRC? Summary from the “*DIRECT*” recommendations and update from the last-year literature.

11.00 am-11.40 am Panel Discussion

eoCRC SURGICAL PATH

Moderators: **Randall E. Brand, Matthew F Kalady, José Gaston Guillem**

11.40 am-12.00 am **Toni Seppala**. What diagnostic workup for eoCRC before surgical treatment? Summary from the “*DIRECT*” recommendations and update from the last-year literature.

12.00 am-12.20 am **Gabriela Moslein**, What modifications to surgical approach can be offered? Summary from the “*DIRECT*” recommendations and update from the last-year literature.

12.20 am – 12.40 am Panel discussion

12.40 am-13.00 Lecture **Alberto Bardelli: “Adaptive Evolution: How Bacteria and Cancer Cells Survive Stressful Conditions and Drug Treatment”**

Introduction: Salvatore Siena

13.00 – 14.00 Lunch break

September 2nd – Afternoon

LIFE DURING END-STAGE DISEASE IN eoCRC

Moderators: Riccardo Caccialanza, Cristina Oliani, Kimmie Ng

14.30 pm-14.50 **Andrea Sartore Bianchi.** Management of cancer-related symptoms in eoCRC, including pain, fatigue, nausea, vomiting, constipation, diarrhea and cachexia? Summary from the “*DIRECT*” recommendations and update from the last-year literature.

14.50 pm-15.10 pm **Carla Ida Ripamonti.** How should supportive care programs be organized, for the better care of patients with eoCRC? Summary from the “*DIRECT*” recommendations and update from the last-year literature.

15.10 pm – 15.30 pm Panel Discussion

PATIENT PERSPECTIVES IN EO-CRC

Moderators: Florian Kuhn, Alberto Malesci

15.30 pm-15.40 pm: **Zorana Maravic,** eoCRC: EU patients’ perspective and engagement

15.40 pm-15.50 pm: **Cindy Borassi** eoCRC: US patients’ perspective and engagement

15.50 pm-16.00 pm **Salvo Testa:** Italy patients’ perspective and engagement

16.00 pm-16.20 pm: Panel Discussion

16.20 pm **Closing remarks**